Cannabidiol and periodontal inflammatory disease: A critical assessment

0557807 - ÚCHP 2023 RIV CZ eng J - Journal Article
Jirásek, P. - Jusku, A. - Šimánek, V. - Franková, J. - Storch, Jan - Vacek, J.
Cannabidiol and periodontal inflammatory disease: A critical assessment.
Biomedical Papers. Roč. 166, č. 2 (2022), s. 155-160. ISSN 1213-8118. E-ISSN 1804-7521
Institutional support: RVO:67985858
Keywords : constituent * sativa * cannabidiol * gingivitis
OECD category: Biochemistry and molecular biology
Impact factor: 0.9, year: 2022
Method of publishing: Open access
https://biomed.papers.upol.cz/pdfs/bio/2022/02/05.pdf

Cannabidiol (CBD), a non-psychotropic cannabinoid produced by the genus Cannabis, is a phytoceutical that activates the endocannabinoid system (ECS) through binding to CB1 and CB2 receptors. The ECS is involved in cellular homeostasis and regulates metabolic processes in virtually all mammalian tissues. Published studies on CBD focus, inter alio, on its use in prophylaxis and as an anti-inflammatory agent. Here the authors present a critical assessment of the effects of CBD on inflammatory periodontal diseases caused by bacterial virulence factors, and evaluate critically the possible benefits and drawbacks of CBD use in dentistry. Particular attention is paid to the interaction of CBD with microbially colonized oral tissues, the inflammatory response in relation to the immune response, and the destruction/regeneration of hard and soft tissues of the periodontium.
Permanent Link: http://hdl.handle.net/11104/0331777